Cost analysis of a clinical pharmacist–led multidisciplinary iron deficiency treatment clinic for patients with heart failure or pulmonary hypertension
American Journal of Health-System Pharmacy · 2025
DOI: 10.1093/ajhp/zxaf113 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Maryam Pathan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Heart Failure, Pharmacists, Hypertension, Pulmonary, Pharmacy Service, Hospital. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Purpose
To conduct a data-driven cost analysis comparing a clinical pharmacist–led iron deficiency treatment clinic to usual care for patients with heart failure (HF) or pulmonary hypertension (PH).
Methods
Direct medical costs for providing services and associated reimbursements over a 19-month period were estimated from the hospital perspective for a group of patients who received iron deficiency treatment in a pharmacist-led clinic and a group that received usual care. The frequency of various services within each group were derived from clinical data of a published cohort study. Unit costs for services were obtained from the literature. The net cost per patient was calculated and compared between groups, with one-way sensitivity analysis conducted on hospitalization and clinical pharmacist personnel costs. All costs were inflated to 2024 US dollar value.
Results
A total of 81 patients received clinical pharmacist–led services, and the cost for the services provided was $3,089 per patient, while 42 received usual care, with a cost of $5,547 per patient. The reimbursement per patient was $1,852 in the clinical pharmacist group and $1,798 in the usual care group. The net cost per patient was lower in the clinical pharmacist group by $2,512 than in the usual care group. One-way sensitivity analyses indicated that varying hospitalization costs significantly impacted the net cost in both groups.
Conclusion
This study demonstrated that a clinical pharmacist–led service incurred lower net cost per patient than usual care, leading to cost savings for the hospital. Economic analyses can complement clinical studies in demonstrating the sustainability of clinical services.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, Morgantown, WV, USA.
- Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, USA.
Zitieren
APA
Pathan, M., Kido, K., & Kamal, K. M. (2025). Cost analysis of a clinical pharmacist–led multidisciplinary iron deficiency treatment clinic for patients with heart failure or pulmonary hypertension. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf113
Vancouver
Pathan M, Kido K, Kamal KM. Cost analysis of a clinical pharmacist–led multidisciplinary iron deficiency treatment clinic for patients with heart failure or pulmonary hypertension. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf113
BibTeX
@article{Pathan2025,
author = {Pathan, Maryam and Kido, Kazuhiko and Kamal, Khalid M},
title = {Cost analysis of a clinical pharmacist–led multidisciplinary iron deficiency treatment clinic for patients with heart failure or pulmonary hypertension},
journal = {American Journal of Health-System Pharmacy},
year = {2025},
doi = {10.1093/ajhp/zxaf113}
}
EUVIMED